$Journey Medical (DERM.US)$ a company to watch out for, top line results phase 3 trials for DFD-29 reported by several healthcare resources.
PDUFA scheduled for early November. If approved, annual market potential exceeding 100 million USD.
PDUFA scheduled for early November. If approved, annual market potential exceeding 100 million USD.
1
Would love to subscribe but as a double tax (corporate and personal) payer PR, i am marginalised (pun intended) by Moomoo and excluded from any malaysian IPO.
the usual run up to earnings with lots of fomo involved
$Phathom Pharmaceuticals (PHAT.US)$ breaking free of the shackles..! up she goes
1
2
$Verona Pharma (VRNA.US)$ Wow, the recent earnings - which was not really earnings yet - gave this a greay boost. pre-market i am officially 100% up !
$Verona Pharma (VRNA.US)$ earnings on 8/8 and hopefully new announcements!
1
1
$Phathom Pharmaceuticals (PHAT.US)$ Lots of nervous trading going on. Once the shake out of shorters has been completed in a few weeks time and with the earnings on 8/8 this baby will go north
3
$Verona Pharma (VRNA.US)$ and finally it seems all brakes are loose and it is going to the top!
1
$Verona Pharma (VRNA.US)$ Price pressure has begun in pre-market, which looks unreal for a company receicing approval for a novel - and potentially groundbreaking - drug.
Stay calm, dont play in the hands of the shorts. Make sure your stock cannot be borrowed for shorts as well.
Stay calm, dont play in the hands of the shorts. Make sure your stock cannot be borrowed for shorts as well.
4
1
$Verona Pharma (VRNA.US)$ shorters will try to push it down. this is a long term hold being a blockbuster drug, with a 2 billion potential further down the road. revenue forecast for this year 40 million. hopefully conference call is giving the price a boost. if a big pharma might do a take over, it goes sky rocketing. whatever it is, don’t sell cheap. Disclaimer: not financial advice.
5